Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

Nature Medicine

Volumn 5, Issue 6, 1999, Pages 677-685

  Lee, Peter P ^a   Yee, Cassian ^b   Savage, Peter A ^a   Fong, Lawrence ^a   Brockstedt, Dirk ^a   Weber, Jeffrey S ^c   Johnson, Denise ^a   Swetter, Susan ^a   Thompson, John ^b   Greenberg, Philip D ^b   Roederer, Mario ^a   Davis, Mark M ^a  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOPHENOL MONOOXYGENASE; TUMOR ANTIGEN;

ARTICLE; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EFFECTOR CELL; HUMAN; HUMAN CELL; MELANOMA; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TARGET CELL; TUMOR GROWTH;

ANTIGENS, CD28; ANTIGENS, CD44; ANTIGENS, CD45; ANTIGENS, CD57; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HLA-A2 ANTIGEN; HUMANS; LYMPHATIC METASTASIS; MELANOMA; MEMBRANE GLYCOPROTEINS; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; RECEPTORS, IGG; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 0033056073     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/9525     Document Type: Article

References (46)

1. Yannelli, J.R. et al. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int. J. Cancer 65, 413-421 (1996).
2. Topalian, S.L., Solomon, D. & Rosenberg, S.A. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol. 142, 3714-3725 (1989).
3. Romero, P. et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188, 1641-1650 (1998).
4. Altman, J.D. et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94-96 (1996).
5. McMichael, A.J. & O'Callaghan, C.A. A new look at T cells. J. Exp. Med. 187, 1367-1371 (1998).
6. Kawakami, Y. & Rosenberg, S.A. Human tumor antigens recognized by T-cells. Immunol. Res. 16, 313-339 (1997).
7. Cormier, J.N. et al. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int. J. Cancer 75, 517-524 (1998).
8. Boon, T. et al. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy. Important Adv. Oncol. 130, 53-69 (1994).
9. Rosenberg, S.A. & White, D.E. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. 19, 81-84 (1996).
10. Ogg, G.S., Dunbar, P.R., Romero, P., Chen, J.L. & Cerundolo, V. High Frequency of Skin-homing Melanocyte-specific Cytotoxic T Lymphocytes in Autoimmune Vitiligo. J. Exp. Med. 188, 1203-1208 (1998).
11. Bell, E.B., Sparshott, S.M. & Bunce, C. CD4+ T-cell memory, CD45R subsets and the persistence of antigen - a unifying concept. Immunol. Today 19, 60-64 (1998).
12. Natali, P.G. et al. Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc. Natl. Acad. Sci. USA 86, 6719-6723 (1989).
13. Maeurer, M.J. et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J. Clin. Invest. 98, 1633-1641 (1996).
14. Callan, M.F. et al. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. 187, 1395-1402 (1998).
15. Hamann, D. et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. J. Exp. Med. 186, 1407-1418 (1997).
16. Trimble, L.A. & Lieberman, J. Circulating CD8 T lymphocytes in human immunodeficiency virus-infected individuals have impaired function and downmodulate CD3 zeta, the signaling chain of the T-cell receptor complex. Blood 91, 585-594 (1998).
17. Ku, C.C., Kotzin, B., Kappler, J. & Marrack, P. CD8+ T-cell clones in old mice. Immunol. Rev. 160, 139-144 (1997).
18. Lahat, N., Rahat, M.A., Sadeh, O., Kinarty, A. & Kraiem, Z. Regulation of HLA-DR and costimulatory B7 molecules in human thyroid carcinoma cells: differential binding of transcription factors to the HLA-DRalpha promoter. Thyroid 8, 361-369 (1998).
19. Barth, R.J., Jr., Camp, B.J., Martuscello, T.A., Dain, B.J. & Memoli, V.A. The cytokine microenvironment of human colon carcinoma. Lymphocyte expression of tumor necrosis factor-alpha and interleukin-4 predicts improved survival. Cancer 78, 1168-1178 (1996).
20. Kawakami, Y. et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180, 347-352 (1994).
21. Sundstedt, A. et al. Superantigen-induced anergy in cytotoxic CD8+ T cells. J. Immunol. 154, 6306-6313 (1995).
22. Chai, J.G., Bartok, I., Scott, D., Dyson, J. & Lechler, R. T:T antigen presentation by activated murine CD8+ T cells induces anergy and apoptosis. J. Immunol. 160, 3655-3665 (1998).
23. Mizoguchi, H. et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258, 1795-1798 (1992).
24. Ochoa, A.C. & Longo, D.L. Alteration of signal transduction in T cells from cancer patients. Imp. Adv. Oncol. 55, 43-54 (1995).
25. Finke, J.H. et al. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 53, 5613-5616 (1993).
26. Nakagomi, H. et al. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 53, 5610-5612 (1993).
27. He, X.S. et al. Quantitative analysis of hepatitis C virus-specific CD8+ T cells in peripheral blood and liver using peptide-MHC tetramers. Proc. Natl. Acad. Sci. USA (in the press).
28. Chambers, C.A. & Allison, J.P. Co-stimulation in T cell responses. Curr. Opin. Immunol. 9, 396-404 (1997).
29. Sperling, A.I. et al. CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. J. Immunol. 157, 3909-3917 (1996).
30. Huang, A.Y. et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-965 (1994).
31. Huang, A.Y. et al. Bone marrow-derived cells present MHC class I-restricted tumour antigens in priming of antitumour immune responses. Ciba Found. Symp. 187, 229-240; discussion 240-224 (1994).
32. Marrogi, A.J. et al. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int. J. Cancer 74, 492-501 (1997).
33. Merogi, A.J. et al. Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. Hum. Pathol. 28, 321-331 (1997).
34. Zajac, A.J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205-2213 (1998).
35. DeGrendele, H.C., Estess, P. & Siegelman, M.H. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 278, 672-675 (1997).
36. Beagley, K.W. & Husband, A.J. Intraepithelial lymphocytes: origins, distribution, and function. Crit. Rev. Immunol. 18, 237-254 (1998).
37. Rocha, B., Vassalli, P. & Guy-Grand, D. Thymic and extrathymic origins of gut intraepithelial lymphocyte populations in mice. J. Exp. Med. 180, 681-686 (1994).
38. Kaminski, M.J., Cruz, P.D., Jr., Bergstresser, P.R. & Takashima, A. Killing of skin-derived tumor cells by mouse dendritic epidermal T-cells. Cancer Res. 53, 4014-4019 (1993).
39. Shiohara, T. & Moriya, N. Epidermal T cells: their functional role and disease relevance for dermatologists. J. Invest. Dermatol. 109, 271-275 (1997).
40. Yee, C., Riddell, S.R. & Greenberg, P.D. Prospects for adoptive T cell therapy. Curr. Opin. Immunol. 9, 702-708 (1997).
41. Maio, M. & Parmiani, G. Melanoma immunotherapy: new dreams or solid hopes? Immunol. Today 17, 405-407 (1996).
42. Maeurer, M.J., Storkus, W.J., Kirkwood, J.M. & Lotze, M.T. New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res. 6, 11-24 (1996).
43. Lee, N. et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl. Acad Sci. USA 95, 5199-5204 (1998).
44. Coulie, P.G. et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180, 35-42 (1994).
45. Riddell, S.R., Reusser, P. & Greenberg, P.D. Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients. Rev. Infect. Dis. 13 Suppl 11, 5966-973 (1991).
46. Yee, C. et al. Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J. Immunol. 157, 4079-4086 (1996).